We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMODX
RNS Number : 6226T
Omega Diagnostics Group PLC
16 October 2017
Omega Diagnostics Group PLC
("Omega" or the "Company")
US Supply Agreement
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has signed a Supply Agreement with a US-based company offering laboratory testing services, specialising in gut health for improved health outcomes.
The agreement, which covers Omega's microarray-based food intolerance product FoodPrint(R), is for an initial term of three years and is automatically renewable thereafter on the mutual agreement of both parties. This agreement will enable the Company to increase traction in the US for FoodPrint(R) which provides laboratories with a high throughput food sensitivity testing solution. Omega expects a modest contribution from this arrangement in the current financial year.
The global market for Food Allergy and Intolerance products is projected to exceed $24.8 billion by 2020, driven by the rise in food hypersensitivity, allergies and associated anaphylaxis as a result of changes in diet and sensitivity to food additives and increased use of sulphur dioxide and sulphites as preservatives. The United States represents the largest market worldwide, led by the ongoing trend of selective food avoidance among the affluent health conscious consumers. (Source: http://www.strategyr.com/pressMCP-6441.asp)
Andrew Shepherd, Chief Executive Officer of Omega, commented: "We are pleased to have signed this agreement that enables us to broaden our food intolerance product offering in the important US market. We are excited by the prospects for this relationship and believe the capabilities of our chosen partner will enable us to deliver better health outcomes for patients."
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030 Andrew Shepherd, Chief Executive www.omegadiagnostics.com Kieron Harbinson, Group Finance Director Jag Grewal, Group Sales and Marketing Director finnCap Ltd Tel: 020 7220 0500 Geoff Nash/James Thompson (Corporate Finance) Mia Gardner (Corporate Broking) Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGREAPESFEEXFEF
(END) Dow Jones Newswires
October 16, 2017 02:00 ET (06:00 GMT)
1 Year Omega Diagnostics Chart |
1 Month Omega Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions